IXICO PLC (LON:IXI) has secured a contract for neuroimaging solutions with a large global pharmaceutical company.
The Phase IIB trial will investigate an orphan drug designated clinical asset for the treatment of Huntington's disease (HD).
The AIM-listed artificial intelligence data analytics company said the contract win was included in management's expectations of performance for the current financial year but adds to the company's strong order book.
"We are delighted to be chosen to take part in this HD study to advance development of promising medical treatments for this devastating rare disease. This contract and new partnership will further endorse our breakthrough neuroimaging technologies with large pharma sponsors across the full spectrum of the drug development pathway,” said Lammert Albers, the chief commercial officer of IXICO in a statement.